Ibrutinib: coming of age?
- PMID: 29699993
- DOI: 10.1182/blood-2018-02-832071
Ibrutinib: coming of age?
Conflict of interest statement
Conflict-of-interest disclosure: J.R.B. has served as a consultant for Janssen, Pharmacyclics, AstraZeneca, Sun, Redx, Sunesis, Loxo, Gilead, TG Therapeutics, Verastem, and AbbVie and receives research funding from Sun and Gilead.
Comment in
-
Ibrutinib and fungus: an invasive concern.Blood. 2018 Apr 26;131(17):1882-1884. doi: 10.1182/blood-2018-02-832154. Blood. 2018. PMID: 29699994 No abstract available.
Comment on
-
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.Blood. 2018 Apr 26;131(17):1910-1919. doi: 10.1182/blood-2017-10-810044. Epub 2018 Feb 2. Blood. 2018. PMID: 29437592 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources